Literature DB >> 33813359

Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial.

Rodrigo Vitorio1, Samuel Stuart2, Andrew Giritharan1, Joseph Quinn1, John G Nutt1, Martina Mancini3.   

Abstract

INTRODUCTION: Cholinergic dysfunction contributes to mobility deficits in Parkinson's disease (PD). People with PD rely on limited prefrontal executive-attentional resources for the control of locomotion, including turning. Cortical and behavioral responses to cholinergic augmentation during turning remains unclear. We examined prefrontal cortex (PFC) activity while turning-in-place and spatiotemporal measures of turns in response to usual dopaminergic medication and adjunct cholinergic augmentation.
METHODS: This study consisted of a single-site, randomized, double-blind crossover trial. Twenty PD participants were assessed in the levodopa-off state and then randomized to either levodopa + donepezil (5 mg) or levodopa + placebo treatments for two weeks followed by a 2-week washout before crossover. The primary outcome was change from off state in PFC activity while turning-in-place (assessed with functional near-infrared spectroscopy). Secondary outcomes were changes in spatiotemporal turning measures (assessed with body-worn inertial measurement units) and accuracy in the secondary task.
RESULTS: Nineteen participants completed the trial. While levodopa + placebo had no effect on PFC activity when turning-in-place with a dual-task, levodopa + donepezil led to a large reduction in PFC activity (effect size, -0.82). Spatiotemporal measures of turning improved with both treatments, with slightly greater effect sizes observed for levodopa + donepezil. Additionally, the accuracy in the concurrent cognitive task improved only with levodopa + donepezil (effect size, 0.63).
CONCLUSION: The addition of cholinergic therapy with donepezil (5 mg/day for 2 weeks) to standard dopaminergic therapy reduced the burden on prefrontal executive-attentional resources while turning with a dual-task and improved secondary task accuracy and turning.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Locomotion; Parkinson's disease; Prefrontal cortex; fNIRS

Mesh:

Substances:

Year:  2021        PMID: 33813359     DOI: 10.1016/j.parkreldis.2021.03.014

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  2 in total

Review 1.  The Cholinergic Brain in Parkinson's Disease.

Authors:  Jacopo Pasquini; David J Brooks; Nicola Pavese
Journal:  Mov Disord Clin Pract       Date:  2021-08-23

2.  α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.

Authors:  Roger L Albin; Martijn L T M Müller; Nicolaas I Bohnen; Cathie Spino; Martin Sarter; Robert A Koeppe; Ashley Szpara; Kamin Kim; Cindy Lustig; William T Dauer
Journal:  Ann Neurol       Date:  2021-05-26       Impact factor: 11.274

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.